It’s not easy fitting the U.S. Food and Drug Administration’s requirements to publish drug information to the public in 140 characters. This month, the FDA issued guidance documents about social media with respect to prescription drugs and medical devices, according to a post by Erin Bosman and Joanna Simon of Morrison & Foerster.
The authors reported last month that the guides were being distributed for comments from the industry. They outline, among other things, when pharmaceutical companies and the like need to correct misinformation promulgated through social media and how to accurately depict the benefit and risk information about products when limited by characters and other constraints of digital forums.
